Next Article in Journal
Angiopoietin-2 Combined with Radiochemotherapy Impedes Glioblastoma Recurrence by Acting in an Autocrine and Paracrine Manner: A Preclinical Study
Next Article in Special Issue
Effects of the Novel PFKFB3 Inhibitor KAN0438757 on Colorectal Cancer Cells and Its Systemic Toxicity Evaluation In Vivo
Previous Article in Journal
Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
Previous Article in Special Issue
Chemosensitivity of Patient-Derived Cancer Stem Cells Identifies Colorectal Cancer Patients with Potential Benefit from FGFR Inhibitor Therapy
 
 
cancers-logo
Article Menu
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Aljabali, A.A.A.; et al. Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer via down Regulation of Nuclear p65 and HIF-1α. Cancers 2020, 12, 113

by
Alaa A. A. Aljabali
1,†,
Hamid A. Bakshi
2,†,
Faruck L. Hakkim
3,
Yusuf A. Haggag
4,
Khalid M. Al-Batanyeh
5,
Mazhar S. Al Zoubi
6,
Bahaa Al-Trad
5,
Mohamed M. Nasef
7,
Saurabh Satija
8,
Meenu Mehta
8,
Kavita Pabreja
8,
Vijay Mishra
8,
Mohammed Khan
2,
Salem Abobaker
9,
Ibrahim M. Azzouz
10,
Harish Dureja
11,
Ritesh M. Pabari
12,
Ashref Ali K. Dardouri
13,
Prashant Kesharwani
14,
Gaurav Gupta
15,
Shakti Dhar Shukla
16,
Parteek Prasher
17,
Nitin B. Charbe
18,
Poonam Negi
19,
Deepak N. Kapoor
19,
Dinesh Kumar Chellappan
20,
Mateus Webba da Silva
2,
Paul Thompson
21,
Kamal Dua
16,19,22,23,
Paul McCarron
2 and
Murtaza M. Tambuwala
2,*,†
add Show full author list remove Hide full author list
1
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Yarmouk University, Irbid 566, Jordan
2
School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine BT52 1SA, Northern Ireland, UK
3
Department of Mathematics and Sciences, College of Arts and Applied Sciences, Dhofar University Salalah, Salalah 211, Oman
4
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Tanta, Tanta 31111, Egypt
5
Department of Biological Sciences, Faculty of Science, Yarmouk University, Irbid 566, Jordan
6
Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid 566, Jordan
7
Department of Pharmacy and Biomedical Sciences, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK
8
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India
9
Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow, Klinikum Charite-Universitatmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
10
Department of Dermatology, Venerology, and Allergology, Charite-Universitatsmedizin Berlin, Freie Universitat Berlin, Chariteplatz1, 10117 Berlin, Germany
11
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, India
12
School of Pharmacy, Royal College of Surgeons in Ireland, D02 YN77 Dublin-09, Ireland
13
Department of Forensic Science, School of Applied Science, Huddersfield University, Queensgate, Huddersfield HD1 3DH, UK
14
Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
15
School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur 302017, India
16
Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI), School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 230, Australia
17
Department of Chemistry, University of Petroleum & Energy Studies, Dehradun 248007, India
18
Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Av. Vicuña McKenna 4860, 7820436, Macul, Santiago 4860, Chile
19
School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173229, India
20
Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia
21
School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, UK
22
Discipline of Pharmacy, Graduate School of Health, University of Technology, Sydney, NSW 2007, Australia
23
Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia
*
Author to whom correspondence should be addressed.
These authors contributed equally to this study.
Cancers 2020, 12(12), 3587; https://doi.org/10.3390/cancers12123587
Submission received: 3 November 2020 / Accepted: 6 November 2020 / Published: 30 November 2020
(This article belongs to the Special Issue Targeting Therapy for Colon Cancer)
The authors wish to make the following corrections to this paper [1]: in Figure 2A,C on page 12, some panels appear to show overlapping areas; all images have been now corrected and the different treatment conditions shows the corresponding representative image.
The original version of Figure 2A,C is:
Cancers 12 03587 i001
And should be replaced with the following Figure 2A,C:
Cancers 12 03587 i002
The authors also wish to make the following corrections to this paper [1]: in Figure 4C on page 14, the images for the control and free PIC were taken from the same source due to human error; we have carefully re-assessed all the images and have corrected this error with the appropriate representative images of the control and free PIC groups.
The original version of Figure 4C is:
Cancers 12 03587 i003
The figure should be replaced with the following Figure 4C with the corrected images:
Cancers 12 03587 i004
We stress that these errors were purely due to human error and oversight, all corrections done do not change the written proportion of the figure legend, interpretation of the results, or the final conclusion of this manuscript. The manuscript will be updated. The authors would like to apologize for any inconvenience caused. All changes have been reviewed and approved by the Academic Editors.

Conflicts of Interest

The authors declare no conflict of interest.

Reference

  1. Aljabali, A.A.A.; Bakshi, H.A.; Hakkim, F.L.; Haggag, Y.A.; Al-Batanyeh, K.M.; Al Zoubi, M.S.; Al-Trad, B.; Nasef, M.M.; Satija, S.; Mehta, M.; et al. Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α. Cancers 2020, 12, 113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Aljabali, A.A.A.; Bakshi, H.A.; Hakkim, F.L.; Haggag, Y.A.; Al-Batanyeh, K.M.; Zoubi, M.S.A.; Al-Trad, B.; Nasef, M.M.; Satija, S.; Mehta, M.; et al. Correction: Aljabali, A.A.A.; et al. Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer via down Regulation of Nuclear p65 and HIF-1α. Cancers 2020, 12, 113. Cancers 2020, 12, 3587. https://doi.org/10.3390/cancers12123587

AMA Style

Aljabali AAA, Bakshi HA, Hakkim FL, Haggag YA, Al-Batanyeh KM, Zoubi MSA, Al-Trad B, Nasef MM, Satija S, Mehta M, et al. Correction: Aljabali, A.A.A.; et al. Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer via down Regulation of Nuclear p65 and HIF-1α. Cancers 2020, 12, 113. Cancers. 2020; 12(12):3587. https://doi.org/10.3390/cancers12123587

Chicago/Turabian Style

Aljabali, Alaa A. A., Hamid A. Bakshi, Faruck L. Hakkim, Yusuf A. Haggag, Khalid M. Al-Batanyeh, Mazhar S. Al Zoubi, Bahaa Al-Trad, Mohamed M. Nasef, Saurabh Satija, Meenu Mehta, and et al. 2020. "Correction: Aljabali, A.A.A.; et al. Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer via down Regulation of Nuclear p65 and HIF-1α. Cancers 2020, 12, 113" Cancers 12, no. 12: 3587. https://doi.org/10.3390/cancers12123587

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop